1.
Aleix Prat #PrecisionOncology
@prat_aleix
what a surprise this morning @idibaps @hospitalclinic @UniBarcelona
thanks so much team! i am getting old a… twitter.com/i/web/status/1…
thanks so much team! i am getting old a… twitter.com/i/web/status/1…
01 Mar 23
copy & paste +upvote -downvote what a surprise this morning @idibaps @hospitalclinic @UniBarcelona 🎉🤦♂️
thanks so much team! i am getting old a… https://t.co/uhqcQhPEYc
2.
Aleix Prat #PrecisionOncology
@prat_aleix
Don't call us we'll call you .It was a great honour & pleasure meeting these heavy weights in the field of breast… twitter.com/i/web/status/1…
Retweet of status by @bin_abeid
20 Jan 23
copy & paste +upvote -downvote Don't call us we'll call you 😂.It was a great honour & pleasure meeting these heavy weights in the field of breast… https://t.co/FMCkxaM9AA
3.
4.
5.
6.
7.
Aleix Prat #PrecisionOncology
@prat_aleix
The #OncoAlertColloquium
January 23-28, 2023
PM CETNoon EST
Free Links Daily
More info:… twitter.com/i/web/status/1…
January 23-28, 2023
PM CETNoon EST
Free Links Daily
More info:… twitter.com/i/web/status/1…
Retweet of status by @OncoAlert
15 Jan 23
copy & paste +upvote -downvote The #OncoAlertColloquium 2⃣0⃣2⃣2⃣
January 23-28, 2023
6⃣PM CET🇪🇺1⃣2⃣Noon EST🇺🇸
Free Links Daily
More info:… https://t.co/igwNzFbaU6
Aleix Prat #PrecisionOncology
@prat_aleix
We did not find any prognostic/predictive role for TILs in a pancancer context
PD-L1, with a 10% cut-off, might… twitter.com/i/web/status/1…
PD-L1, with a 10% cut-off, might… twitter.com/i/web/status/1…
Retweet of status by @FrancescoSche20
11 Jan 23
copy & paste +upvote -downvote 🛑We did not find any prognostic/predictive role for TILs in a pancancer context
👉PD-L1, with a 10% cut-off, might… https://t.co/z6S6xm2Jmw
Aleix Prat #PrecisionOncology
@prat_aleix
#HER2DX looks at tumor size, nodal status, and 4 gene expression signatures relating to immune infiltration, proli… twitter.com/i/web/status/1…
Retweet of status by @TotalHealthConf
09 Dec 22
copy & paste +upvote -downvote 🎯#HER2DX looks at tumor size, nodal status, and 4 gene expression signatures relating to immune infiltration, proli… https://t.co/ybWTxgnJxJ
Aleix Prat #PrecisionOncology
@prat_aleix
18th ASEICA International Congress
Early bird registration
Deadline: 3 October 2022
Take a look
Outstan… twitter.com/i/web/status/1…
Early bird registration
Deadline: 3 October 2022
Take a look
Outstan… twitter.com/i/web/status/1…
23 Sep 22
copy & paste +upvote -downvote 🛑18th ASEICA International Congress
Early bird registration↩️
⏰Deadline: 3 October 2022
Take a look👀
Outstan… https://t.co/Pk3LMVriw2
Aleix Prat #PrecisionOncology
@prat_aleix
Our new article is out!
Quality of life (QoL) from @_SOLTI CORALLEEN phase II trial
Great work led by… twitter.com/i/web/status/1…
Quality of life (QoL) from @_SOLTI CORALLEEN phase II trial
Great work led by… twitter.com/i/web/status/1…
06 Sep 22
copy & paste +upvote -downvote 📢Our new article is out!
Quality of life (QoL) from @_SOLTI CORALLEEN phase II trial
Great work led by… https://t.co/OBgWo6qst8
8.
9.
10.
11.
Aleix Prat #PrecisionOncology
@prat_aleix
Trodelvy Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the… twitter.com/i/web/status/1…
15 Aug 22
copy & paste +upvote -downvote Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the… https://t.co/cW6AAN3sMm
Aleix Prat #PrecisionOncology
@prat_aleix
Trastu/pertu sc: HER2+ early BC & met BC
Trastuzumab deruxtecan: HER2+ met BC
Sacituzumab Govitecan: Triple Nega… twitter.com/i/web/status/1…
Trastuzumab deruxtecan: HER2+ met BC
Sacituzumab Govitecan: Triple Nega… twitter.com/i/web/status/1…
Retweet of status by @TomasPascualMD
10 Jun 22
copy & paste +upvote -downvote ❌Trastu/pertu sc: HER2+ early BC & met BC
❌Trastuzumab deruxtecan: HER2+ met BC
❌Sacituzumab Govitecan: Triple Nega… https://t.co/xjkwIFz05n
Aleix Prat #PrecisionOncology
@prat_aleix
Some drugs with indication approved in breast cancer by the EMA and pending or rejected in Spain.
Pertuzumab: ad… twitter.com/i/web/status/1…
Pertuzumab: ad… twitter.com/i/web/status/1…
Retweet of status by @TomasPascualMD
10 Jun 22
copy & paste +upvote -downvote Some drugs with indication approved in breast cancer by the EMA and pending or rejected in Spain.
❌Pertuzumab: ad… https://t.co/9gP4ATLGX3
Aleix Prat #PrecisionOncology
@prat_aleix
1/5 Finally! The RIBOLARIS trial starts! @_SOLTI @GroupeUNICANCER
gruposolti.org/ensayosclinico…
NCT05296746
Very ha… twitter.com/i/web/status/1…
gruposolti.org/ensayosclinico…
NCT05296746
Very ha… twitter.com/i/web/status/1…
22 Apr 22
copy & paste +upvote -downvote 1/5 📢 Finally! The RIBOLARIS trial starts! @_SOLTI @GroupeUNICANCER
https://t.co/FERVGgqZYr
NCT05296746
Very ha… https://t.co/7dfrHehFVR
...but wait! There's more!
1.
fakhright
@fakhright
astaghfirullah peng.krim guaaaaaaaa..............a *salto sambil solat*
14 Jan 13
copy & paste +upvote -downvote astaghfirullah peng.krim guaaaaaaaa..............a *salto sambil solat* 🙈🙈🙊